Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4187 Target Snapshot

Sodium channel protein type 2 subunit alpha · SINGLE PROTEIN · Homo sapiens

332Compounds
157Assays
6Approved Drugs
235.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q99250. Use UniProt Q99250 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q99250 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Sodium channel protein type 2 subunit alpha as ChEMBL target CHEMBL4187, mapped to UniProt Q99250. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Sodium channel protein type 2 subunit alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4187
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q99250
Sodium channel protein type 2 subunit alpha
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Sodium channel protein type 2 subunit alpha is the right protein anchor across sources, using UniProt Q99250 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSodium channel protein type 2 subunit alpha
UniProt AccessionQ99250
Component TypeProtein
Sequence Length2005 aa

Sodium channel protein type 2 subunit alpha

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Sodium channel protein type 2 subunit alpha, mapped to UniProt Q99250. Sequence length is 2005 aa.

Mapped IDQ99250
Review nameSodium channel protein type 2 subunit alpha
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

6
Approved
3
Phase III
5
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC50215.0
KI12.0
EC505.0
KD3.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3617063 9.7 IC50 0.2 Preclinical
CHEMBL4060338 9.55 IC50 0.28 Preclinical
CHEMBL501134 9.0 IC50 1.0 Preclinical
CHEMBL3662190 8.7 IC50 2.0 Preclinical
CHEMBL4070670 8.7 IC50 2.0 Preclinical
CHEMBL4217988 8.6 IC50 2.519 Preclinical
CHEMBL3341983 8.38 IC50 4.2 Preclinical
CHEMBL4064160 8.28 EC50 5.3 Preclinical
CHEMBL3662077 8.22 IC50 6.0 Preclinical
CHEMBL4290579 8.15 IC50 7.0 Preclinical
Distribution

pChEMBL Value Distribution

47
5.0
44
5.5
21
6.0
17
6.5
10
7.0
9
7.5
6
8.0
6
8.5
2
9.0
2
9.5
pChEMBL
Approved Drugs

Approved Drugs

TETRACAINE
CHEMBL698
Approved 2005
Assay Landscape

Assay Landscape

157
Total Assays
160
Tested Compounds
3
Assay Types
Binding — 145 assays, 160 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 92 106 6.0
single protein format 41 50 5.7
assay format 12 4 5.4
ADME — 10 assays, 10 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 9 9 6.6
single protein format 1 1 7.5
Functional — 2 assays, 4 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 4 5.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine